What is Alpha Preclinical?
Based in Massachusetts, Alpha Preclinical operates as a critical partner for organizations navigating the complexities of drug discovery and medical technology development. The company provides a comprehensive suite of laboratory services, including IVIS imaging, colony management, and specialized surgical procedures. By offering tailored preclinical models for gene therapy, autoimmune disorders, and oncology, Alpha Preclinical bridges the gap between early-stage research and clinical application. Their market position is defined by a commitment to personalized scientific solutions that accelerate the development of next-generation therapies.
How much funding has Alpha Preclinical raised?
Alpha Preclinical has raised a total of $700K across 1 funding round:
Debt
$700K
Debt (2025): $700K with participation from Chase
Key Investors in Alpha Preclinical
Chase
A global financial services firm providing comprehensive banking and investment solutions to support large-scale corporate growth and capital structure optimization.
What's next for Alpha Preclinical?
With this recent influx of capital, Alpha Preclinical is well-positioned to scale its operational capacity and expand its portfolio of research models. The company is expected to leverage these resources to enhance its laboratory infrastructure, potentially increasing its throughput for complex fibrosis and metabolic disease studies. As the demand for outsourced preclinical research continues to rise, Alpha Preclinical's strategic focus on high-fidelity data and specialized service offerings will likely serve as a catalyst for further growth and industry partnerships. The firm remains focused on supporting the rigorous requirements of modern therapeutic innovation.
See full Alpha Preclinical company page
